Should I order a Fibrosis‑4 (Fib‑4) score with reflex to an Enhanced Liver Fibrosis (ELF) assay, or just obtain a Fib‑4 level?

Order FIB-4 with Reflex to ELF

For patients with NAFLD/MASLD, you should order a FIB-4 with reflex to ELF testing rather than FIB-4 alone. This sequential approach is the guideline-endorsed strategy that optimizes detection of advanced fibrosis while minimizing unnecessary referrals and costs.

The Sequential Testing Algorithm

The recommended pathway works as follows:

1. First-line: FIB-4 score (calculated from age, ALT, AST, platelet count)

   • FIB-4 <1.3 (or <2.0 if age >65): Low risk—reassure patient, no further testing needed 1, 2
   • FIB-4 ≥1.3 (or ≥2.0 if age >65): Indeterminate/high risk—reflex to ELF testing 2

2. Second-line: ELF test (for indeterminate FIB-4 results)

   • ELF <9.5-9.8: Low risk—can manage in primary care
   • ELF ≥9.5-9.8: High risk for advanced fibrosis—refer to hepatology 2, 3, 4

Why This Sequential Approach Is Superior

High negative predictive value: FIB-4 <1.3 has an NPV of 92.7% for ruling out advanced fibrosis, allowing you to confidently reassure low-risk patients 1. This avoids unnecessary testing in the majority of patients.

Cost-effectiveness: The Camden and Islington pathway using this sequential strategy resulted in a 5-fold increase in detection of advanced fibrosis, 3-fold increase in cirrhosis detection, and 81% reduction in inappropriate referrals compared to no structured pathway 2. Multiple studies confirm this approach is both clinically effective and cost-saving 2, 5.

Improved accuracy for indeterminate cases: ELF testing in the indeterminate FIB-4 group (1.3-2.67) provides superior discrimination. Studies show ELF has significantly fewer false positives (11%) compared to using FIB-4 alone (35%) or NAFLD Fibrosis Score (45%), while maintaining low false negative rates (<8%) 5.

Critical Pitfalls to Avoid

Do not use FIB-4 alone without a reflex strategy: FIB-4 ≥1.3 has limited sensitivity (57%) and will miss 43% of patients with fibrotic MASLD if used as a standalone gatekeeper 6. The sequential reflex to ELF overcomes this limitation.

Age considerations: Neither FIB-4 nor NFS are validated in patients <35 years old—interpret with caution in young patients 2. For patients >65, use age-adjusted cutoffs (FIB-4 <2.0 instead of <1.3) 2.

Avoid ordering ELF on everyone: While concurrent testing (FIB-4 and ELF simultaneously) improves sensitivity to 87% 6, it is not cost-effective for population screening. Reserve this approach only for high-risk populations where missing cases has severe consequences.

Supporting Evidence for the Reflex Strategy

The sequential FIB-4→ELF approach correctly classifies 88% of cases, with only 8% false positives and 4% false negatives 5. When combined, FIB-4 ≥1.3 followed by ELF ≥9.8 achieves 67.9% sensitivity, 90.4% specificity, 75.2% PPV, and 86.8% NPV for advanced fibrosis 4. This strategy excluded 71.8% of patients from unnecessary liver biopsies in real-world practice 4.

ELF demonstrates superior prognostic value: In biopsy-controlled cohorts, ELF provides risk stratification for liver-related events comparable to liver histology and liver stiffness measurement, with event rates of 1% for ELF <9.8,27.8% for ELF 9.8-11.3, and 72.7% for ELF ≥11.3 7.

Practical Implementation

Order as: "FIB-4 score with reflex to Enhanced Liver Fibrosis (ELF) test if FIB-4 ≥1.3"

This ensures the laboratory automatically performs ELF testing only when needed, streamlining the pathway and reducing delays in risk stratification. The reflex approach is validated in primary care settings and does not require additional equipment beyond standard laboratory capabilities 4.